Focusing on the prevention and treatment of diabetes and chronic kidney disease, Keshenda is listed to open the "Golden Triangle" era of diabetic kidney treatment | diabetes | listed
On July 15, the first national marketing conference of Keshenda, a non steroidal selective mineralocorticoid receptor antagonist approved for type 2 diabetes related chronic kidney disease, was held in Shanghai. Many experts in the fields of kidney disease, endocrinology and cardiovascular gathered online and offline to discuss clinical needs, challenges, new therapies and other focus topics, and talk about the change of treatment concept of diabetes related chronic kidney disease and the diagnosis and treatment opportunities brought by new products.
![Focusing on the prevention and treatment of diabetes and chronic kidney disease, Keshenda is listed to open the "Golden Triangle" era of diabetic kidney treatment | diabetes | listed](https://a5qu.com/upload/images/75e9b48eb4f02444b2ef88c78fe055b1.png)
There are nearly 120 million patients with chronic kidney disease in China, including about 31.08 million patients with chronic kidney disease caused by type 2 diabetes. Nearly 40% of type 2 diabetes patients will develop chronic kidney disease. More worrisome is that diabetes related chronic kidney disease has gradually become the main cause of end-stage renal disease in China, which seriously affects the prognosis and quality of life of patients.
![Focusing on the prevention and treatment of diabetes and chronic kidney disease, Keshenda is listed to open the "Golden Triangle" era of diabetic kidney treatment | diabetes | listed](https://a5qu.com/upload/images/030c473d84e0b7fe29ec51e9a5dafd1b.png)
DKD clinical management faces two major challenges
![Focusing on the prevention and treatment of diabetes and chronic kidney disease, Keshenda is listed to open the "Golden Triangle" era of diabetic kidney treatment | diabetes | listed](https://a5qu.com/upload/images/edb96a62765020a89b5bb73a9ce4ed7f.png)
Professor Mu Yiming, Director of the Endocrinology Department of the General Hospital of the People's Liberation Army, introduced that at present, DKD is a major difficulty in clinical management, and disease management mainly faces two major challenges:
![Focusing on the prevention and treatment of diabetes and chronic kidney disease, Keshenda is listed to open the "Golden Triangle" era of diabetic kidney treatment | diabetes | listed](https://a5qu.com/upload/images/35213e0bc55f4f5a66a9f5835ed851cd.jpg)
The first challenge is the low awareness rate, screening rate and treatment rate of diabetes related kidney disease.
The data shows that the annual screening rate of DKD in China is only 55.1% to 73.3%; The awareness rate of patients with diabetes kidney disease about their kidney injury is less than 20%. The treatment rate of RAS inhibitors in patients with proteinuria is less than 20%, and the rate of reaching the standard of blood glucose control in all patients with diabetes and kidney disease is less than 40% (HbA1c